Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Provectus Biopharmaceuticals Inc PVCT

Healthcare
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing immunotherapy medicines for different diseases that are based on a class of synthetic small-molecule immuno-catalysts called halogenated xanthenes (HXs). The Company’s lead molecule is named rose bengal sodium (RBS). The Company’s small molecule HX medical science platform... see more

Recent & Breaking News (OTCQB:PVCT)

Provectus Biopharmaceuticals Receives Notice of Allowance for Refractory Pediatric Solid Tumor Cancer Monotherapy and Combination Therapy Patent for PV-10® Immunotherapy from United States Patent and Trademark Office

GlobeNewswire March 23, 2021

Provectus Biopharmaceuticals Announces Release of Preprint Manuscript Describing Preclinical Study of PV-10® Immunotherapy and Chemotherapy for Treatment of Pancreatic Cancer

GlobeNewswire January 20, 2021

Provectus Biopharmaceuticals Announces Oral Presentation of Updated Data from Combination Therapy Trial of PV-10® and Keytruda® for Checkpoint-Refractory Advanced Cutaneous Melanoma at Melanoma Bridge 2020

GlobeNewswire December 7, 2020

Provectus Biopharmaceuticals Announces Presentation of PV-10® Pancreatic Cancer Data at 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

GlobeNewswire November 16, 2020

Provectus Biopharmaceuticals Announces Acceptance of PV-10® Melanoma Abstract for Oral Presentation at Melanoma Bridge 2020

GlobeNewswire November 12, 2020

Provectus Biopharmaceuticals Announces Acceptance of PV-10® Pancreatic Cancer Abstract at 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

GlobeNewswire October 15, 2020

Provectus Biopharmaceuticals Completes Enrollment of PV-10® Study for Treatment of Symptomatic Neuroendocrine Tumors Metastatic to the Liver Refractory to Somatostatin Analogs and Peptide Receptor Radionuclide Therapy

GlobeNewswire October 5, 2020

Provectus Biopharmceuticals Highlights Stage IV M1d Patient Outcome from Combination Therapy Trial of PV-10® and KEYTRUDA® for Checkpoint-Refractory Advanced Cutaneous Melanoma at ESMO Virtual Congress 2020

GlobeNewswire September 21, 2020

Provectus Biopharmaceuticals Highlights Stage IV M1c Patient Outcome from Combination Therapy Trial of PV-10® and KEYTRUDA® for Checkpoint-Naïve Advanced Cutaneous Melanoma at ESMO Virtual Congress 2020

GlobeNewswire September 21, 2020

Provectus Biopharmaceuticals Announces Presentation of Preliminary Data from Combination Therapy Trial of PV-10® and KEYTRUDA® for Checkpoint-Refractory Advanced Cutaneous Melanoma at ESMO Virtual Congress 2020

GlobeNewswire September 17, 2020

Provectus Biopharmaceuticals Announces Presentation of 2-Year Landmark Data from Combination Therapy Trial of PV-10® and KEYTRUDA® for Checkpoint-Naïve Advanced Cutaneous Melanoma at ESMO Virtual Congress 2020

GlobeNewswire September 17, 2020

Provectus Biopharmaceuticals Establishes Research Collaboration with University of Tennessee Health Science Center to Investigate Small Molecule Rose Bengal Disodium for Antibiotic Resistance

GlobeNewswire September 9, 2020

Provectus Biopharmaceuticals Expands Sponsored Research Collaboration with University of Calgary (Canada) to Investigate Oral Administration of Rose Bengal Disodium for Cancer Treatment

GlobeNewswire August 13, 2020

Provectus Biopharmaceuticals Announces Acceptance of Two PV-10® Melanoma Cancer Abstracts at European Society for Medical Oncology (ESMO) Virtual Congress 2020

GlobeNewswire July 22, 2020

Provectus Biopharmaceuticals Announces Change to Board of Directors

GlobeNewswire July 16, 2020

Provectus Biopharmaceuticals Announces Discovery of Unique PV-10®-Induced STING Pathway Mechanism for Presentation at American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II

GlobeNewswire June 22, 2020

Provectus Biopharmaceuticals Expands Global Patent Portfolio to India for Cancer Combination Therapy

GlobeNewswire June 9, 2020

Provectus Announces Presentation of Updated Data from Metastatic Uveal Melanoma Cohort of Phase 1 PV-10® Study at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program

GlobeNewswire June 1, 2020

Provectus Announces Publication of Updated Data from Metastatic Neuroendocrine Phase 1 PV-10® Study at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program

GlobeNewswire June 1, 2020

Provectus Announces PV-10® STING Agonist Abstract at American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II

GlobeNewswire May 18, 2020